Study of raludotatug deruxtecan for ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous or high-grade endometrioid.
- Your cancer has either come back after treatment or is newly diagnosed at an advanced stage.
- You have had between 1 and 3 prior lines of treatment (the exact number depends on the study group).
- You have tumor tissue available for testing, and you are able to provide a new sample if needed.
- You are in generally good health (able to carry out daily activities) and have not had certain serious heart, lung, or blood vessel problems recently.
- You have not had certain prior treatments with specific drugs, and you are not currently on chronic steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
This study tests a new investigational drug, raludotatug deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as maintenance treatment after second-line platinum-based chemotherapy for recurrent ovarian cancer. The goal is to keep the cancer from growing longer.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Hear when a new Ovarian Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.